Loading...

APGE APOGEE THERAPEUTICS INC Product Launches 8-K Filing

PG T

PG

APOGEE THERAPEUTICS INC

(APGE)

2024 8-K

Show Summary

Show Summary

Clinical Trials

Financial Results

Clinical Trial Update

Clinical Trial Launch

Financial Results

Clinical Trial Update

Clinical Trial Launch

Financial Results

Meeting Results

Appointment of Director

Earnings Report

Presentation of Phase 1 Data

Financial Results and Phase...

Financial Results Announcement

Appointment of Mark C. McKe...

External Links:

Apogee Therapeutics, Inc. has initiated dosing in patients with atopic dermatitis in its Phase 2 clinical trial for APG777, a monoclonal antibody targeting inflammation.

AI Assistant

APOGEE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.